Juric, Dejan <br/><br/>
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.  [electronic resource] 

 -  JAMA oncology  02 2019 
 - e184475 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2018.4475  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--chemistry<br/>Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors<br/>Disease Progression<br/>Estrogen Receptor Antagonists--administration & dosage<br/>Female<br/>Fulvestrant--administration & dosage<br/>Humans<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Mutation<br/>Progression-Free Survival<br/>Protein Kinase Inhibitors--administration & dosage<br/>Receptors, Estrogen--analysis<br/>Thiazoles--administration & dosage<br/>Time Factors